December 18, 2017 RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Cell Microsystems, a provider of innovative tools and scalable solutions for the sorting and isolation of single cells, announced today it is accelerating the development of new products based on its CellRaft™ Technology and expanding their availability in the marketplace. The CellRaft Technology, which allows researchers to easily... Read more
Germantown, Maryland, and Hilden, Germany, December 15, 2017 – QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN’s QuantiFERON®-TB... Read more
Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation Germantown, Maryland, and Hilden, Germany, December 15, 2017 – QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a settlement in the lawsuit in the U.S. District... Read more
Germantown, Maryland, and Hilden, Germany, December 08, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it is transferring the U.S. listing of its global shares to the New York Stock Exchange (NYSE) from the NASDAQ Global Market. The transfer to the NYSE is expected to be effective on or about... Read more
Germantown, Maryland, and Hilden, Germany, December 08, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it is transferring the U.S. listing of its global shares to the New York Stock Exchange (NYSE) from the NASDAQ Global Market. The transfer to the NYSE is expected to be effective on or about January... Read more
First bioinformatics solution integrating new AMP/ASCO/CAP standards for NGS cancer testing to confidently and quickly report clinical relevance of somatic mutations Hilden, Germany, and Germantown, Maryland, November 15, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched enhancements in its QIAGEN Clinical Insight (QCI) bioinformatics software automating the AMP/ASCO/CAP Standards and Guidelines for... Read more
Hilden, Germany, and Germantown, Maryland, November 15, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched enhancements in its QIAGEN Clinical Insight (QCI) bioinformatics software automating the AMP/ASCO/CAP Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer, advancing precision medicine with the first solution to offer molecular pathologists... Read more
Hilden, Germany, and Germantown, Maryland, November 14, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new studies highlighting the outstanding analytical performance and ease of use of the GeneReader NGS System, the world’s first complete Sample to Insight solution for next-generation sequencing. The studies are being presented this week at the... Read more
Outstanding and unmatched capabilities fuel strong growth in installed base and consumables use on highly versatile Sample to Insight automation solution Hilden, Germany, and Germantown, Maryland, November 13, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the 2,000th placement of QIAsymphony, the leading Sample to Insight workflow automation solution for molecular laboratories... Read more
Hilden, Germany, and Germantown, Maryland, November 13, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the 2,000th placement of QIAsymphony, the leading Sample to Insight workflow automation solution for molecular laboratories worldwide. The milestone means QIAGEN has already exceeded its year-end 2017 goal of exceeding 2,000 cumulative placements. The rapid dissemination... Read more